Lehr Martin A. 4

What Happened

• Martin A. Lehr, Chief Executive Officer of Context Therapeutics (CNTX), received a derivative equity award covering 815,000 shares on February 19, 2026. The award was reported as acquired at $0.00 (i.e., no cash paid at grant) and is a grant/award (transaction code A), not an immediate sale or exercised option.

Key Details

• Transaction date: 2026-02-19; filing date: 2026-02-23 (timely filing).
• Amount: 815,000 derivative shares (award/option) granted; reported acquisition price $0.00.
• Shares owned following transaction: not specified in the Form 4 filing.
• Footnote: The award vests over four years — 25% on February 19, 2027, then monthly vesting over the remaining three years, subject to continued service (per filing footnote).
• Filing timeliness: Report filed within the required reporting window; not flagged as late.

Context

• This was an award of derivative securities (an equity grant/option), not an exercise or sale. The grant creates potential future ownership as the award vests; no shares were sold or exercised at grant date.
• Such grants are typically part of executive compensation and do not by themselves indicate immediate buying or selling of stock.